List of Excipients in Branded Drug LORATADINE ODT

« Back to Dashboard

Generic Drugs Containing LORATADINE ODT

Company	Ingredient	NDC	Excipient
WALGREEN CO	loratadine	0363-9937	ASPARTAME
WALGREEN CO	loratadine	0363-9937	CELLULOSE, MICROCRYSTALLINE
WALGREEN CO	loratadine	0363-9937	CROSPOVIDONE
WALGREEN CO	loratadine	0363-9937	MANNITOL

What are the Most Frequently-Used Excipients in LORATADINE ODT?

# Of NDCs	Excipient
19	ASPARTAME
13	CELLULOSE, MICROCRYSTALLINE
6	CROSCARMELLOSE SODIUM
13	CROSPOVIDONE

Loratadine ODT Excipient Strategy and Commercial Opportunities

Last updated: September 27, 2026

Loratadine orally disintegrating tablets, or ODTs, offer a low-cost reformulation opportunity in the mature antihistamine market. The strongest commercial position is a fast-disintegrating, low-moisture product with acceptable taste, low tablet weight, robust packaging, and a clear differentiation claim such as sugar-free, low-sodium, alcohol-free, or easier administration for pediatric and geriatric patients.

The active ingredient is a poorly water-soluble, lipophilic antihistamine. Formulation success depends less on chemical novelty than on taste masking, rapid wetting, powder flow, tablet mechanical strength, moisture control, and scalable manufacturing. Basic loratadine composition-of-matter protection has expired. Commercial barriers now center on formulation performance, regulatory execution, trademarks, manufacturing economics, and channel access.

What excipients are best suited for loratadine ODT formulations?

A loratadine ODT generally requires five excipient functions: soluble or rapidly dispersible bulk, superdisintegration, taste masking, compression support, and moisture protection.

Formulation function	Preferred excipient classes	Commercial rationale
Diluent and mouthfeel	Mannitol, lactose, sucrose, isomalt, sorbitol	Mannitol provides cooling sensation and low hygroscopicity
Superdisintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup at low tablet weight
Binder	Copovidone, povidone, low-substituted hydroxypropyl cellulose	Improves mechanical strength without slowing disintegration excessively
Lubricant	Sodium stearyl fumarate, magnesium stearate	Supports ejection and manufacturing throughput
Glidant	Colloidal silicon dioxide	Improves flow in direct compression
Taste masking	Ion-exchange resin, polymer coating, lipid coating, cyclodextrin, sweetener-flavor system	Reduces bitterness and aftertaste
Saliva stimulation	Citric acid, malic acid, effervescent acid-base systems	Can improve wetting and sensory perception
Flavor and sweetener	Sucralose, aspartame, acesulfame potassium, peppermint, fruit flavors	Supports pediatric and consumer acceptance
Moisture control	Low-moisture excipients, desiccants, high-barrier blister	Protects disintegration and mechanical properties

Mannitol is usually the leading diluent for a premium ODT because it is relatively nonhygroscopic, compressible in suitable grades, and produces a cooling mouthfeel. Direct-compression mannitol grades can reduce process complexity. Spray-dried mannitol or co-processed mannitol systems can improve flow and compactability.

Crospovidone is often preferred when rapid water uptake and tablet breakup are priorities. Croscarmellose sodium can provide strong swelling but may increase sensitivity to formulation water activity. Sodium starch glycolate is effective but may produce variable performance if overused or poorly distributed.

Sodium stearyl fumarate can be considered where magnesium stearate is associated with excessive hydrophobicity or delayed wetting. Lubricant level and blending time require tight control because over-lubrication can reduce tablet hardness and slow disintegration.

Which excipient combinations offer the strongest commercial profile?

Three formulation platforms are commercially credible.

Mannitol-crospovidone direct compression

This is the lowest-complexity platform. It can use a high proportion of mannitol, a superdisintegrant, colloidal silicon dioxide, lubricant, sweetener, and flavor.

The advantages are low capital requirements, short process development, and compatibility with standard tablet presses. The primary risk is that uncoated loratadine can generate unacceptable bitterness. A direct-compression product therefore requires either an effective flavor system or a taste-masked loratadine intermediate.

Taste-masked loratadine with a mannitol matrix

In this platform, loratadine is coated or adsorbed onto a carrier before blending with mannitol and disintegrant. Suitable approaches include polymer-coated particles, ion-exchange resin complexes, lipid-coated particles, and fluid-bed granules.

This approach improves sensory performance and can support a premium product. It raises manufacturing cost, particle-size control requirements, and process-validation burden. Coating materials must not create a delayed-release profile or reduce dose uniformity.

Granulated ODT with co-processed excipients

Wet granulation is generally less attractive for a moisture-sensitive ODT unless the active is protected or the process is designed around controlled residual moisture. Dry granulation or roller compaction can improve flow and content uniformity while avoiding water exposure.

Co-processed excipients can reduce development time, but their supplier-specific composition may create procurement risk and complicate alternate-source qualification.

How should loratadine taste masking be designed?

Taste masking is the principal technical differentiator for loratadine ODT.

Loratadine is practically insoluble in water, but the small amount that dissolves in saliva can still produce bitterness. Taste evaluation should measure both immediate bitterness and delayed aftertaste because a formulation that passes a short sensory screen may fail during actual oral residence.

Taste-masking approach	Benefits	Key risks
High-intensity sweetener and flavor	Low cost and simple process	Often insufficient for persistent bitterness
Ion-exchange resin complex	Strong taste reduction and established technology	May affect drug release and dose uniformity
Polymer-coated particles	Flexible control of release and taste	Coating uniformity and residual solvent concerns
Lipid coating	Good barrier and pleasant mouthfeel	Potential impact on dissolution and scale-up
Cyclodextrin complex	Can improve apparent solubility and taste	Cost, dose loading, and complexation control
Adsorption onto porous carrier	Simple incorporation into powder blend	May provide incomplete taste masking

A practical development sequence is to screen uncoated loratadine with a high-mannitol matrix, then compare resin-complexed and polymer-coated active if sensory performance is inadequate. The development target should include:

• Disintegration within the applicable ODT specification and internal target.
• Rapid loratadine release under immediate-release conditions.
• No clinically meaningful delay relative to the reference product.
• Acceptable mouthfeel after 30 to 60 seconds.
• Low friability despite low tablet hardness.
• Stable assay and dissolution after accelerated storage.

Taste masking cannot be allowed to create a sustained-release effect. FDA guidance treats ODTs as immediate-release dosage forms when they disintegrate rapidly and release the drug promptly. The final product must demonstrate pharmaceutical equivalence and bioequivalence to the selected reference product where the application proceeds under an abbreviated pathway.[1]

What manufacturing process is most suitable for loratadine ODT?

Direct compression is normally the preferred first-line process. It minimizes water exposure, reduces unit operations, and supports low-cost manufacturing.

A representative process architecture is:

1. Sieve or de-lump loratadine and functional excipients.
2. Preblend the active with a portion of diluent.
3. Add the remaining diluent and superdisintegrant.
4. Blend flavor and sweetener under controlled shear.
5. Add glidant.
6. Add lubricant for a short final blend.
7. Compress at controlled force and speed.
8. Package immediately in high-barrier materials.

Critical process parameters include blend time, lubricant addition time, compression force, turret speed, feeder speed, and tablet ejection behavior. Critical quality attributes include assay, content uniformity, disintegration, dissolution, friability, hardness, water activity, and sensory acceptability.

Roller compaction is a useful backup where direct compression produces poor flow or segregation. Wet granulation should be reserved for formulations that cannot achieve content uniformity or tablet strength by dry processing.

A low tablet weight is commercially desirable but technically difficult. Very small tablets can create dose-uniformity, friability, and embossing problems. A practical target is a tablet that is substantially smaller than a conventional swallowed tablet but large enough to support robust compression and packaging.

What packaging protects loratadine ODT stability?

Moisture protection is central to ODT commercialization. Exposure to humidity can change tablet hardness, increase disintegration time, alter mouthfeel, and destabilize flavor systems.

Blister packaging

Cold-form aluminum or high-barrier thermoform blisters provide the strongest consumer-facing protection. They also support unit-dose dispensing and help prevent tablets from being crushed during transport.

Bottles

Bottles have lower packaging cost but require a high-barrier container, desiccant, controlled headspace, and strong patient instructions. Bottles are less attractive where the tablet is mechanically fragile.

Packaging strategy

Market position	Preferred package
Premium pediatric or travel product	Unit-dose aluminum blister
Pharmacy-value generic	High-barrier bottle with desiccant
Institutional supply	Multi-unit bottle or unit-dose blister
Humidity-sensitive formulation	Cold-form aluminum blister

Stability programs should include long-term and accelerated conditions under ICH Q1A(R2), with specific attention to dissolution and disintegration after humidity exposure.[2] Packaging selection should occur before pivotal stability batches, not after formulation lock.

What FDA regulatory pathway applies to loratadine ODT?

A new loratadine ODT may follow one of three regulatory routes.

Abbreviated New Drug Application

An ANDA is the principal pathway for a generic product referencing an approved immediate-release loratadine product. The applicant must establish pharmaceutical equivalence and bioequivalence, comply with current good manufacturing practice, and address any applicable patent certifications.

For an ODT, the reference product must be selected carefully. The dosage form, strength, route, release characteristics, labeling, and inactive-ingredient profile must support the proposed application.

Over-the-counter monograph pathway

Loratadine is widely marketed as an OTC antihistamine. An OTC monograph pathway may be relevant where the proposed product satisfies the applicable monograph conditions, labeling requirements, dosage limits, and active-ingredient standards. The exact pathway depends on the product’s formulation, claims, labeling, and regulatory status.

New Drug Application

An NDA may be appropriate for a differentiated product with a novel delivery technology, proprietary taste-masking system, new indication, or commercial strategy that does not fit a standard generic or monograph approach. This route has higher development cost and a longer regulatory timeline but can create stronger formulation or method-of-use positioning.

What patents protect loratadine ODT products?

The original loratadine compound and basic antihistamine protection are no longer the primary commercial barriers in the United States. Patent risk now arises from narrower claims involving:

• Orally disintegrating compositions.
• Taste-masked loratadine particles.
• Resin complexes.
• Specific excipient ratios.
• Particle-size distributions.
• Coating polymers and coating thickness.
• Manufacturing methods.
• Packaging systems.
• Pediatric dosing or administration methods.
• Combination products containing loratadine and another active ingredient.

The FDA Orange Book remains relevant for approved NDA products and listed patent information, but OTC status and product-specific listing practices require review in the current FDA databases.[3] An applicant should not assume that the absence of a basic loratadine patent eliminates all formulation risk.

Paragraph IV and generic entry risk

A generic applicant may submit a Paragraph IV certification against an unexpired listed patent. The filing can trigger patent litigation and, if the NDA holder receives timely notice, a statutory stay of approval under the Hatch-Waxman framework.[4]

For a conventional loratadine ODT, the likely risk profile is:

Risk category	Assessment
Basic compound patent	Low
Standard immediate-release tablet claims	Low to moderate
Branded ODT formulation claims	Moderate
Taste-masking technology	Moderate to high if claims remain active
Manufacturing-process claims	Product- and jurisdiction-specific
Method-of-use claims	Usually limited for a routine antihistamine indication
Trade dress and trademark disputes	Moderate for consumer products

Patent clearance should distinguish between the active ingredient, the dosage form, the excipient system, the manufacturing process, and the package. A noninfringing formulation may still face trademark or trade-dress constraints if its packaging closely resembles Claritin or another established brand.

When does loratadine lose exclusivity?

Loratadine’s core market exclusivity has already expired in major markets. Generic competition has been established for years, and the active ingredient is commercially mature.

The relevant commercial question is not when loratadine loses basic exclusivity. It is whether a particular ODT formulation has surviving patents, regulatory exclusivity, or channel advantages that delay substitution.

Exclusivity layer	Current commercial significance
Loratadine compound protection	Expired
Standard immediate-release generic entry	Established
Branded ODT formulation	Potentially differentiated by formulation and trademark
New pediatric or combination indication	Depends on specific approval and patent status
Proprietary taste-masking technology	May create formulation-specific protection
Manufacturing process	Potentially relevant if claims are active and difficult to design around

No broad biologic or biosimilar issue applies. Loratadine is a small molecule, so the competitive threat comes from chemical generics, private-label OTC products, and retailer-owned brands rather than biosimilars.

What commercial opportunities exist for loratadine ODT?

The largest opportunities are in product differentiation, channel economics, and geographic expansion.

Pediatric and geriatric administration

ODTs eliminate the need to swallow a conventional tablet. This supports use by children, older adults, and patients who have difficulty swallowing. Pediatric commercialization requires age-appropriate labeling, dose flexibility, palatability testing, and careful control of sweeteners and flavor systems.

Sugar-free and low-calorie positioning

Mannitol, sucralose, and high-intensity sweeteners can support sugar-free positioning. This may matter in diabetes-focused retail channels and for consumers seeking lower-calorie products. Aspartame can create labeling and patient-population considerations, making sucralose or acesulfame potassium attractive alternatives.

Premium private-label products

Retailers can use loratadine ODT as a private-label platform with lower active-ingredient cost and simpler consumer messaging. The best target is a high-volume seasonal allergy category where blister packaging and taste masking support a moderate price premium.

Institutional and travel markets

Blister-packed ODTs are convenient for hospitals, nursing facilities, schools, military supply, and travel kits. The product can be positioned around unit-dose administration and portability rather than new pharmacology.

Geographic licensing

Loratadine is broadly recognized, but excipient permissions, food-color requirements, labeling language, and OTC classification vary by jurisdiction. Licensing opportunities are strongest where a local company has retail distribution and the product can be registered as an established active ingredient in a new dosage form.

Potential regional priorities include:

• United States: ANDA, OTC, and private-label competition.
• European Union: national or decentralized generic procedures, depending on the product and member state.
• Canada: generic or nonprescription drug pathways.
• Latin America: local registration, branding, and retail distribution.
• Asia-Pacific: price-sensitive generic markets with demand for pediatric and senior-friendly dosage forms.

How does loratadine ODT compare with competing antihistamines?

Loratadine ODT competes with cetirizine, levocetirizine, desloratadine, and fexofenadine products.

Attribute	Loratadine ODT	Cetirizine ODT	Fexofenadine ODT
Sedation perception	Generally low	Higher consumer concern in some users	Generally low
Formulation maturity	High	High	High
Taste-masking need	Significant	Significant	Significant
Active ingredient cost	Low	Low	Moderate
Brand recognition	Strong	Strong	Strong
Differentiation potential	Taste, packaging, pediatric use	Price and rapid symptom relief	Non-sedating positioning
Patent barrier	Generally low at active-ingredient level	Generally low at active-ingredient level	Product-specific review required

Loratadine has strong consumer recognition and a mature supply base. Its weakness is limited pharmacological differentiation, which makes sensory quality, package convenience, and retail execution decisive.

What generic launch scenarios exist for loratadine ODT?

Three launch models are realistic.

Value generic

The product uses direct compression, a standard sweetener-flavor system, bottle packaging, and a low-cost excipient platform. This strategy competes on price and retailer access.

Premium generic

The product uses taste-masked loratadine, high-barrier blister packaging, sugar-free labeling, and pediatric-friendly flavor. It can command a higher price but requires stronger evidence for sensory performance and stability.

Licensed technology product

A manufacturer licenses a proprietary taste-masking or ODT platform and supplies multiple strengths or private-label variants. The licensor gains royalty revenue; the manufacturer reduces development time and may obtain a differentiated product profile.

Commercial revenue is likely to be seasonal and channel-dependent. The principal exposure is to price erosion, retailer consolidation, and substitution by conventional tablets, chewables, liquids, and competing antihistamines.

How strong is the patent estate for loratadine ODT?

The broad patent estate is weak because loratadine is an established generic active ingredient. A specific ODT product can still have a moderate formulation estate if it uses a defensible taste-masking system, narrow excipient ratios, a distinct particle-engineering method, or a validated manufacturing process.

Patent strength should be assessed against four factors:

1. Claim breadth and the number of independent claims.
2. Ease of designing around the claimed excipient or process combination.
3. Evidence supporting unexpected taste, dissolution, or stability results.
4. Remaining term and enforceability in target markets.

A formulation patent based only on routine substitution of mannitol, crospovidone, and sweetener is less defensible than a patent supported by comparative sensory data, dissolution evidence, stability results, and a specific particle or coating architecture.

Key Takeaways

• Loratadine ODT is a mature, low-cost reformulation opportunity rather than a novel-drug opportunity.
• Mannitol, crospovidone, controlled lubrication, and high-barrier packaging provide a strong starting platform.
• Taste masking is the main technical and commercial differentiator.
• Direct compression is usually the preferred manufacturing route.
• Loratadine’s core exclusivity has expired; formulation patents and proprietary technologies require product-specific clearance.
• The most attractive segments are pediatric, geriatric, sugar-free, private-label, travel, and institutional markets.
• Premium blister packaging can protect stability and support a price premium.
• No biosimilar risk applies because loratadine is a small-molecule drug.
• Generic price erosion is likely unless the product has credible sensory, packaging, or channel differentiation.
• Patent value is strongest where formulation claims are supported by non-routine taste, dissolution, stability, or manufacturing data.

FAQs

Is loratadine suitable for an orally disintegrating tablet?

Yes. Loratadine is suitable for ODT development because the product can improve administration convenience without changing the established antihistamine mechanism. The formulation must control bitterness, wetting, disintegration, and moisture exposure.

Which excipient is best for loratadine ODT mouthfeel?

Mannitol is usually the leading mouthfeel excipient because it provides a cooling sensation and relatively low hygroscopicity. It should be combined with an effective taste-masking and sweetener system.

Can loratadine ODT be manufactured by direct compression?

Yes. Direct compression is generally the most efficient process if the loratadine powder and excipients provide adequate flow, content uniformity, compactability, and sensory performance.

Are loratadine ODT products exposed to biosimilar competition?

No. Loratadine is a chemically synthesized small molecule. Competitive pressure comes from generic tablets, chewables, liquids, other antihistamines, private-label products, and branded OTC products.

What is the strongest commercial claim for a new loratadine ODT?

The strongest claim is usually a combination of rapid oral disintegration, acceptable taste, sugar-free composition, convenient unit-dose packaging, and suitability for patients who have difficulty swallowing. Such claims require product-specific substantiation and compliant labeling.

References

1. U.S. Food and Drug Administration. (2008). Guidance for industry: Submission of documentation in applications for orally disintegrating tablets. FDA.

2. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

5. U.S. Food and Drug Administration. (1997). 21 CFR Part 331: Antacid products for over-the-counter human use. FDA.

6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.